Exceptional People and Culture

The lifeblood of our company is our exceptional people and culture. We have purposefully built the team with a focus on passionate scientists and company-builders who have hands-on experience translating groundbreaking science into important new medicines.

Katrine Bosley
Katrine Bosley
Chief Executive Officer

Katrine joined Editas Medicine as President Chief Executive Officer in 2014, shortly after the company was founded. Katrine has been part of the biotechnology industry for over 25 years. Before Editas, she was Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, and prior to that, she was President and CEO of Avila Therapeutics. Earlier, Katrine was Vice President, Business Development at Adnexus Therapeutics, and she held several positions at Biogen in business development, commercial operations,...

Read More

Charles Albright, Ph.D.
Charles Albright, Ph.D.
Chief Scientific Officer

Charlie joined Editas Medicine as Chief Scientific Officer in August 2016. He brings more than 25 years of life sciences industry and academic leadership experience, most recently serving as vice president of genetically defined diseases and genomics at Bristol-Myers Squibb (BMS). Over his career, Charlie has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain, psychiatry, oncology and inflammation. Prior to his position as...

Read More

Gerald Cox, M.D., Ph.D.
Gerald Cox, M.D., Ph.D.
Chief Medical Officer

Gerry joined Editas Medicine as Chief Medical Officer in 2016. Previously, he held senior clinical development roles at Sanofi Genzyme (formerly Genzyme Corporation) for over 15 years, most recently as Vice President of Rare Disease Clinical Development. He was instrumental in the development and approval of treatments for lysosomal storage disorders, including the enzyme replacement therapies Aldurazyme® (iduronidase) for Mucopolysaccharidosis type I in 2003, Myozyme® (alglucosidase alfa) for Pompe disease in 2006, Elaprase® (idursulfase)...

Read More

Andrew Hack, M.D., Ph.D.
Andrew Hack, M.D., Ph.D.
Chief Financial Officer

Andrew joined Editas Medicine as CFO in July 2015. Previously, he served as a portfolio manager at Millennium Management, where he ran a healthcare fund focused on biotechnology, pharmaceutical and medical device companies from May 2011 to June 2015. Prior to Millennium, Andrew was an analyst at HealthCor Management from December 2008 to May 2011. Prior to HealthCor Management, Andrew was an analyst Carlyle-Blue Wave Partners and a principal of the MPM BioEquities Fund. He started his investment career covering the biotechnology sector...

Read More

Timothy D. Hunt, J.D.
Timothy D. Hunt, J.D.
Senior Vice President of Corporate Affairs

Prior to joining Editas Medicine, Tim served as senior vice president of public affairs for Cubist Pharmaceuticals, before the company was acquired by Merck in 2015. Before joining Cubist, Tim spent several years at Biogen Idec, where he most recently served as vice president of public affairs, overseeing global communications. Previously, Tim also served in government affairs for GlaxoSmithKline, as well as for former Massachusetts governor, William F. Weld. Tim received his J.D. from the Columbus School of Law at the Catholic University...

Read More

Vic Myer, Ph.D.
Vic Myer, Ph.D.
Chief Technology Officer

Prior to joining Editas Medicine, Vic served as executive director and Cambridge site head for the developmental and molecular pathways department at the Novartis Institutes for Biomedical Research Incorporated (NIBR), where he also served as a research investigator, led the high-throughput biology team and oversaw the target discovery technologies platform. Vic was also a founding scientist and group leader at Akceli, Inc., a venture-backed systems-biology company focusing on commercialization of a high-throughput cell-based micro-array...

Read More

James Mullen

James C. Mullen joined the Editas Medicine Board of Directors as Chairman of the Board in March of 2018.  Jim is a biotech leader with more than 30 years of experience building leading biotechnology and pharmaceutical organizations on a global scale.  Previously, Mr. Mullen served as Chief Executive Officer of Patheon N.V., a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. in August 2017. Before joining Patheon, Mr. Mullen served as Chief Executive Officer and President at Biogen, one of the world's largest biotechnology companies. Prior to being named Chief Executive Officer, Mr. Mullen held various operating positions at Biogen, including Chief Operating Officer, Vice President, International, and Vice President, Operations.  Before joining Biogen, he held several manufacturing and engineering positions at SmithKline Beecham.

Mr. Mullen also serves  on the Board of Directors of Insulet Corporation and Vicarius Pharma AG.  He previously served on the Board of Directors of Patheon, Biogen, and PerkinElmer.  He was also Chairman of the Board of Directors of the Biotechnology Innovation Organization. 

Mr. Mullen holds a Bachelor of Science in Chemical Engineering from Rensselaer Polytechnic Institute and a Master of Business Administration from Villanova University.  

Read More

Kevin Bitterman
Partner, Atlas Venture

Kevin Bitterman is a Partner with Atlas Venture where he focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Mr. Bitterman was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra, and co-founded Genocea Biosciences (NASDAQ: GNCA). He previously served as a director of InSeal Medical, Kala Pharmaceuticals, Neuronetics, Taris Biomedical (acquired by Allergan) and Vets First Choice, among other ventures. Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004.

Mr. Bitterman is active in the local life science and healthcare start-up community, serving on the Scientific Advisory Board of the Massachusetts Life Sciences Center (MLSC) and as Board Chair of the New England Venture Capital Association (NEVCA).  He received a BA in biology, summa cum laude, from Rutgers University before completing his Ph.D. in genetics at Harvard Medical School.  He has published numerous scientific articles and is an inventor on several issued patents.

Read More

Katrine Bosley
Chief Executive Officer, Editas Medicine

Katrine joined Editas Medicine as President Chief Executive Officer in 2014, shortly after the company was founded. Katrine has been part of the biotechnology industry for over 25 years. Before Editas, she was Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, and prior to that, she was President and CEO of Avila Therapeutics. Earlier, Katrine was Vice President, Business Development at Adnexus Therapeutics, and she held several positions at Biogen in business development, commercial operations, and portfolio strategy. She was also part of the healthcare team at the venture firm Highland Capital Partners. She is a graduate of Cornell University.

In addition to her role at Editas, Katrine currently serves as Chairman of the Board of Genocea Biosciences (NASDAQ: GNCA) and is a member of the Board of Directors of Galapagos NV (EURONEXT and NASDAQ: GLPG), of BIO – the Biotechnology Innovation Organization, and of Massachusetts Eye and Ear.

Read More

Andrew Hirsch
Chief Financial Officer, Agios

Andrew Hirsch joined the Editas board of directors in May 2017 with more than 20 years of experience in a range of strategic and operating business roles, including more than 15 years in the biotech industry. Since September 2016, he has served as Chief Financial Officer at Agios, a biopharmaceutical company in the fields of cancer metabolism and rare genetic diseases. Prior to joining Agios, Mr. Hirsch served as President and Chief Executive Officer of BIND Therapeutics and previously as Chief Financial Officer at Avila Therapeutics until its acquisition by Celgene. Prior to that, he held roles of increasing responsibility during his nearly 10-year tenure at Biogen, including Vice President of Corporate Strategy and M&A, as well as Program Executive for the Tecfidera development team.

Mr. Hirsch holds an MBA from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania.

Read More

Jessica Hopfield

Jessica Hopfield is a scientist and business leader with more than two decades of experience in the medical and healthcare fields. She joined the Editas Medicine board of Directors in February, 2018.  Dr. Hopfield is currently the Chairperson of the Board of Trustees of the Joslin Diabetes Center and serves as Lead Independent Director on the Board of Directors of Insulet Corporation. In addition, she is a she is a strategic advisor and investor in start-up healthcare firms, including serving as a strategic advisor to and former independent director of rEVO Biologics. Dr. Hopfield is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice, where she led work in strategy, R&D management, and marketing across pharmaceutical, biotech, medical device and consumer industries. Dr. Hopfield also held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing.

Dr. Hopfield earned a Bachelor of Science from Yale College, a Master of Business Administration from Harvard Graduate School of Business Administration as a Baker Scholar, and a Doctor of Philosophy in Neuroscience/Biochemistry from The Rockefeller University. 

Read More

Boris Nikolic
Managing Director, bng0 and Biomatics Capital

Boris Nikolic has served as a member of the Editas board of directors since August 2015.  Dr. Nikolic is the co-founder and Managing Partner of Biomatics Capital, a venture capital fund investing in transformational innovation at the intersection of health care and technology. He is also the Managing Director of the investment fund bng0, LLC. He currently serves on the board of eGenesis, Inc. and Omniome, Inc., both private biotechnology companies. 

Prior to founding Biomatics Capital and bng0, Dr. Nikolic served as Chief Advisor for Science and Technology to Bill Gates at bgC3, the private office of Bill Gates, where he led investments in life science, IT, and healthcare companies. Dr. Nikolic also worked with the Bill & Melinda Gates Foundation where he focused on biotechnology investments and, in partnership with the Program-Related Investment Team, pioneered direct equity investments in new companies with promising platform technologies. Previously, Dr. Nikolic was an Assistant Professor in Medicine at Harvard Medical School where he led an advanced immunology laboratory for tolerance induction and stem-cell transplantation at Massachusetts General Hospital/Harvard Medical School. 

Dr. Nikolic earned his M.D. from the Zagreb Medical School in Zagreb, Croatia and completed his postdoctoral fellowship in transplantation immunology at Harvard Medical School.

Read More

Akshay Vaishnaw
Executive Vice President of Research and Development at Alnylam Pharmaceuticals

Dr. Vaishnaw, Executive Vice President of Research and Development at Alnylam Pharmaceuticals, Inc. joined the Editas board of directors in July 2016. He has served as Alnylam’s Executive Vice President of Research and Development since December 2014 and as their Chief Medical Officer from June 2011-December 2016. Dr. Vaishnaw also served Alnylam in a number of senior R&D roles of increasing responsibility since joining the company in 2006. From December 1998 through 2005, he held various positions at Biogen Inc. 

Dr. Vaishnaw received his M.D. from the University of Wales College of Medicine, U.K., and his Ph.D. from the University of London, U.K., in molecular immunology. He is also a Fellow of the Royal College of Physicians, U.K. He serves on the board of directors of Visterra Inc., and the scientific advisory board of Scholar Rock Inc.

Read More

Feng Zhang, Ph.D.
Core Member, Broad Institute of MIT and Harvard; Investigator, McGovern Institute for Brain Research, Massachusetts Institute for Technology; W.M. Keck Career Development Professor, Departments of Brain and Cognitive Sciences and Biological Engineering, Massachusetts Institute of Technology; Robertson Investigator, New York Stem Cell Foundation

Feng Zhang joined the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard as a core member in 2011. Dr. Zhang is also an investigator at the McGovern Institute for Brain Research at MIT and an assistant professor at MIT with a joint appointment in the departments of brain and cognitive sciences and biological engineering. As a student, he played a major role in the development of optogenetics, a technology that allows the brain’s electrical activity to be controlled with light-sensitive proteins. He is now working to extend this molecular engineering approach to other aspects of brain function, such as gene expression, and to develop new approaches to understanding and eventually treating brain diseases. Dr. Zhang is a Searle Scholar and has received both a Director’s Transformative Research Award and a Directors? Pioneer Award from the National Institutes of Health. In 2012, he shared the UNC/Perl Prize for his role in the development of optogenetics.

Dr. Zhang holds an A.B. in chemistry and physics from Harvard College and a Ph.D. in chemistry from Stanford University.

Read More

George Church, Ph.D.
Professor of Genetics, Health Sciences and Technology, Harvard University and MIT; Director of the HMS NHGRI-Center of Excellence in Genomic Science; Director of the Personal Genome Project, Broad Institute and Wyss Harvard Institute of Biologically Inspired Engineering

George Church is a leading expert in human genetics and biotechnology. He has served as professor of genetics at Harvard Medical School since 1986 and currently serves as professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology (MIT). He is also director of the U.S. Department of Energy Center on Bioenergy at Harvard and MIT and director of the National Institutes of Health Center of Excellence in Genomic Science at Harvard. Dr. Church helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. Dr. Church pioneered genome engineering, systems and synthetic biology, and concepts of molecular multiplexing and tags, and he has a successful track record of developing and transferring new technologies to more than 20 companies. Dr. Church has received numerous awards, including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the 2009 Promega Biotechnology Research Award from the American Society for Microbiology, and was honored in The Scientist’s Top 10 Innovations list in 2008.

Dr. Church holds a Ph.D. in biochemistry and molecular biology from Harvard University and a B.A. in zoology and chemistry from Duke University.

Read More

J. Keith Joung, M.D., Ph.D.
Associate Chief of Pathology for Research and Pathologist, Massachusetts General Hospital; Professor of Pathology, Harvard Medical School

J. Keith Joung currently serves as professor of pathology at Harvard Medical School and is associate chief of pathology for research and the Jim and Ann Orr Research Scholar at Massachusetts General Hospital (MGH). He is also a member of the Center for Cancer Research and Center for Computational and Integrative Biology at MGH.

Dr. Joung has been a pioneer in the development of important technologies for targeted genome editing and epigenome editing of human cells. He has received numerous awards including an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the Jim and Ann Orr MGH Research Scholar Award, and election into the American Association of University Pathologists. He is a Scientific Advisory Board member of Horizon Discovery and Transposagen Biopharmaceuticals.

Dr. Joung holds a Ph.D. in genetics from Harvard University, an M.D. from Harvard Medical School and an A.B. in biochemical sciences from Harvard College.

Read More

David R. Liu, Ph.D.
Investigator, Howard Hughes Medical Institute; Professor of Chemistry and Chemical Biology, Harvard University; Vice-Chair of the Faculty and Core Faculty Member, Broad Institute of MIT and Harvard

David R. Liu is an accomplished chemist, biologist, and innovator. He currently serves as professor of chemistry and chemical biology at Harvard University, investigator of the Howard Hughes Medical Institute investigator, and vice-chair of the faculty and core institute member of the Broad Institute of Harvard and MIT. His research has advanced the fields of therapeutics discovery, laboratory evolution, macromolecular delivery, and genome editing.  Dr. Liu’s insight and breadth led him to be tapped to serve as a JASON, an elite group of scientists who advise the U.S. government on matters of science and technology. Dr. Liu is also the recipient of numerous scientific distinctions, including the American Chemical Society Pure Chemistry and Arthur C. Cope Young Scholar Awards, the GlaxoSmithKline Chemistry Scholar Award, the AstraZeneca Pharmaceuticals Excellence in Chemistry Award, the Searle Scholars Award, the National Science Foundation (NSF) Faculty Early Career Development (CAREER) Award, the Sloan Foundation Fellowship, the Beckman Foundation Young Investigator Award, the Office of Naval Research Young Investigator Award and the university-wide Roslyn Abramson Award for undergraduate teaching at Harvard. Dr. Liu was named to the Popular Science “Brilliant 10” for young scientists in the U.S., as well as to the MIT TR100 for young innovators. In 2016 he was named one of the Top 20 Translational Researchers by Nature Biotechnology.  His accomplishments also include groundbreaking research leading to the foundation of Ensemble Therapeutics and Permeon Biologics.

Dr. Liu holds a B.A. in chemistry from Harvard College and a Ph.D. in organic chemistry from the University of California, Berkeley. 

Read More